Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura

British Journal of Cancer

Volumn 88, Issue 10, 2003, Pages 1553-1559

  Edwards, J G ^a,b   McLaren, J ^c   Jones, J L ^c   Waller, D A ^b   O'Byrne, K J ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Malignant mesothelioma; Matrix metalloproteinases; Prognosis

Indexed keywords

GELATINASE A; GELATINASE B;

ANGIOGENESIS; ARTICLE; BENIGN TUMOR; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MALIGNANT MESOTHELIOMA; METASTASIS; MULTIVARIATE ANALYSIS; PLEURA TUMOR; PLEURISY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; ZYMOGRAPHY;

ADULT; AGED; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MESOTHELIOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL;

EID: 0038115843     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600920     Document Type: Article

References (61)

1. Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K, Eguchi K (2002) Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 35: 1117-1124
2. Antony VB, Hott JW, Godbey SW, Holm K (1996) Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8. Chest 109: 21S-22S
3. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR (2000) Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60: 4629-4637
4. Baker EA, Bergin FG, Leaper DJ (2000) Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 87: 1215-1221
5. Baker EA, Leaper DJ (2002) Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol 28: 24-29
6. Bielefeldt-Ohmann H, Jarnick A, Fitzpatrick D (1996) Molecular pathobiology and immunology of malignant mesothelioma. J Pathol 178: 369-378
7. Bissett D, O'Byrne KJ, von Pawel J, Mercier R, Price A, Nicholson M, Shepherd F, Mazabel E, Penning C, Zhang MH, Collier MA (2002) Phase III study of the matrix metalloproteinase (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer. Proc ASCO 21: 296a
8. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW (2002a) Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86: 1864-1870
9. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA (2002b) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161-167
10. Brown PD, Bloxidge RE, Anderson E, Howell A (1993a) Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 11: 183-189
11. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J (1993b) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85: 574-578
12. Cox D (1972) Regression models and life tables. J Roy Stat Soc 34: 187-220
13. Cox G, Jones JL, Andi A, Waller DA, O'Byrne KJ (2000a) Molecular biological staging system for operable non-small cell lung cancer. Thorax 56: 561-566
14. Cox G, Jones JL, O'Byrne KJ (2000b) Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6: 2349-2355
15. Cox G, Steward W, O'Byrne K (1999) The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax 54: 169-179
16. Cox G, Walker RA, Andi A, Steward WP, O'Byrne KJ (2000c) Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 29: 169-177
17. Curran D, Sahmoud T, Therasse P, Van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organisation for Research and Treatment of Cancer Experience. J Clin Oncol 16: 145-152
18. DeClerck YA (2000) Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer 36: 1258-1268
19. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostor AG, Nie G, Lopata A, Salamonsen LA (2002) Presence of active gelatinases in endometrial carcinoma and matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 94: 1466-1475
20. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL (1994) Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74: 762-766
21. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, Wright A (1999) Preclinical and clinical studies of MMP inhibitors in cancer. Ann NY Acad Sci 878: 228-235
22. Edwards J, Cox G, Andi A, Jones J, Walker R, Waller D, O'Byrne K (2001) Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85: 865-868
23. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55: 731-735
24. Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, O'Connor CM (1997) Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Resp Crit Care Med 156: 240-247
25. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL (1994) Tumor angiogenesis in node-negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29: 109-116
26. Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR (2000) Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83: 1147-1153
27. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113: 723-731
28. Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ (1994) Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 14: 246-258
29. Ikebe T, Shinohara M, Takeuchi H, Beppu M, Kurahara S, Nakamura S, Shirasuna K (1999) Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis 17: 315-323
30. Jones JL, Walker RA (1997) Control of matrix metalloproteinase activity in cancer. J Pathol 183: 377-379
31. Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A, Papakonstantinou E, Vretou E, Mirtsou-Fidani V (1997) Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 17: 158-168
32. Kikuchi R, Noguchi T, Takeno S, Kubo N, Uchida Y (2000) Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br J Cancer 83: 215-218
33. Kumar-Singh S, Vermeulen PB, Weyler J, Segers K, Weyn B, Van Daele A, Dirix LY, Van Oosterom AT, Van Marck E (1997) Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 182: 211-216
34. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E (1999) Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 189: 72-78
35. Lengyel E, Schmalfeldt B, Konik E, Spathe K, Harting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W (2001) Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 82: 291-298
36. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F (1996) Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56: 190-196
37. Liu Z, Ivanoff A, Klominek J (2001) Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer 91: 638-643
38. Maatta M, Soini Y, Liakka A, Autio-Harmainen H (2000) Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 6: 2726-2734
39. Maekawa R, Maki H, Yoshida H, Hojo K, Tanaka H, Wada T, Uchida N, Takeda Y, Kasai H, Okamoto H, Tsuzuki H, Kambayashi Y, Watanabe F, Kawada K, Toda K, Ohtani M, Sugita K, Yoshioka T (1999) Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res 59: 1231-1235
40. Maguire PD, Qi W, Lallemand R, Scully SP (2000) Gelatinase and inhibitor expression in soft tissue sarcomas: lack of correlation with distant metastasis. Oncology 59: 139-144
41. Martin-Ucar AE, Edwards JG, Rengarajan A, Muller S, Waller DA (2001) Palliative debulking surgery in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg 20: 1117-1121
42. Mautino G, Oliver N, Chanez P, Bousquet J, Capony F (1997) Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Resp Cell Molec Biol 17: 583-591
43. Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, Tournier JM, Birembaut P (1997) Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer 72: 556-564
44. O'Byrne KJ, Cox G, Swinson D, Richardson D, Edwards JG, Lolljee J, Andi A, Koukourakis MI, Giatromanolaki A, Gatter K, Harris AL, Waller D, Jones JL (2001) Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer 34 (suppl 2): S83-S89
45. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y, Pass HI (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81: 54-61
46. Pan MR, Chuang LY, Hung WC (2001) Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 508: 365-368
47. Papathoma AS, Petraki C, Grigorakis A, Papakonstantinou H, Karavana V, Stefanakis S, Sotsiou F, Pintzas A (2000) Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 20: 2009-2013
48. Polette M, Birembaut P (1998) Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol 30: 1195-1202
49. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HL, Suffredini AF (1999) Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Resp Cell Mol Biol 20: 458-464
50. Reich R, Martin GR (1996) Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 51: 1-17
51. Rusch V (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 108: 1122-1128
52. Rusch VW, Piantadosi S, Holmes EC (1991) The role of extrapleural pneumonectomy in malignant mesothelioma: a Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 102: 1-9
53. Schwartz GK (1996) Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol 23: 316-324
54. Sterman DH, Kaiser LR, Albelda SM (1999) Advances in the treatment of malignant pleural mesothelioma. Chest 116: 504-520
55. Steward W (1999) Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 43 (Suppl): S56-S60
56. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp Jr MM, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117: 54-63
57. Sugarbaker DJ, Norberto JJ (1998) Multimodality management of malignant pleural mesothelioma. Chest 113: 61S-65S
58. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M (1995) Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 64: 355-359
59. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Muller KM (1998) Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124: 291-296
60. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T (2002) Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 86: 1876-1883
61. Yorioka CW, Coletta RD, Alves F, Nishimoto IN, Kowalski LP, Graner E (2002) Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int J Oncol 20: 189-194